Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study
Clinical Rheumatology · 2024
DOI: 10.1007/s10067-024-07161-6 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Rheumatology, 2024. Verfasst von Po-Cheng Shih und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Changhua Christian Hospital, No. 135, NanXiao Street, Changhua, 50…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Pyrimidines, Piperidines, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
To investigate the incidence of the discontinuation among tofacitinib and biologic disease-modifying anti-rheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA). This retrospective population-based cohort study included 5,008 RA patients who initiated treatment with either tofacitinib or bDMARDs (etanercept, adalimumab, golimumab, tocilizumab, or abatacept) between January 1, 2014, and December 31, 2020. We conducted Cox proportional hazards regression and subsequent time-dependent regression to assess the risk of drug discontinuation, with adjustments for potential variables. The highest drug discontinuation rate was observed with etanercept (43.27%), while the lowest was with tofacitinib (21.8%). Tofacitinib was associated with a significantly lower risk of discontinuation compared to etanercept (HR: 0.67, 95% CI: 0.57-0.80) and other bDMARDs. Higher steroid dosage and the presence of concomitant connective tissue diseases were significant risk factors for drug discontinuation. Conversely, the use of methotrexate was associated with a reduced risk of discontinuation. Tofacitinib demonstrated a lower risk of drug discontinuation compared to TNFi, with the risk factors for discontinuation including higher steroid dosage and concomitant connective tissue diseases. The study highlights the importance of considering several potential risk factors in drug discontinuation. Key Points • Non-TNFi biologic agents demonstrated better drug retention than TNFi among patients diagnosed with rheumatoid arthritis, with tofacitinib showing the lowest discontinuation rate (21.8%), underscoring its potential for superior drug retention in rheumatoid arthritis management. • Several factors were associated with drug discontinuation: higher steroid dosage and concomitant connective tissue diseases were linked to a higher discontinuation rate, whereas the concomitant use of methotrexate was associated with a lower risk of discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Changhua Christian Hospital, No. 135, NanXiao Street, Changhua, 500, Taiwan. robertpcshih@gmail.com.
- Institute of Medicine, Chung Shan Medical University, South District, No. 110, Sec. 1, Jianguo N. Rd., Taichung, 40201, Taiwan. robertpcshih@gmail.com.
- School of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan.
- Institute of Medicine, Chung Shan Medical University, South District, No. 110, Sec. 1, Jianguo N. Rd., Taichung, 40201, Taiwan.
- Department of Medicine, Chung Shan Medical University Hospital, Taichung, 402, Taiwan.
- Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, 402, Taiwan.
Zitieren
APA
Shih, P. C., Hung, P. C., Leong, P. Y., Hsu, J. N., Yang, C. C., Wei, J. C. C., & Chen, H. H. (2024). Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07161-6
Vancouver
Shih PC, Hung PC, Leong PY, Hsu JN, Yang CC, Wei JCC, et al. Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study. Clinical Rheumatology. 2024. doi:10.1007/s10067-024-07161-6
BibTeX
@article{Shih2024,
author = {Shih, Po-Cheng and Hung, Po-Cheng and Leong, Pui-Ying and Hsu, Jui-Ning and Yang, Chieh-Chun and Wei, James Cheng Chung and Chen, Hsin-Hua},
title = {Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study},
journal = {Clinical Rheumatology},
year = {2024},
doi = {10.1007/s10067-024-07161-6}
}
EUVIMED